News
Novartis' 'wild card' drug Scemblix gets FDA nod for leukaem...
Novartis has claimed FDA approval for one of its 'wild card' drugs – Scemblix – a first-in-class STAMP inhibitor for patients with previously-treated chronic myeloid leukaemia (CML).
